Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in relapsed/refractory multiple myeloma
NCT02726581Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of nivolumab in multiple myeloma (MM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression Free Survival up to 64 months. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02726581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726581.